Aplexis, Inc.

Wilmette, IL · Biotech · Private

Small molecule inhibitors targeting Pleckstrin-2 (Plek2) to treat thrombosis in myeloproliferative neoplasms

Grants
$2.6M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis$397,198
Federal grantDepartment of Health and Human Services · Phase II · Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis$1,101,337
Federal grantDepartment of Health and Human Services · Phase II · Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis$1,101,337
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3260NeuroFx, Inc.——
3261Tessa Therapeutics——
3262Oblenio Bio——
3263Aplexis, Inc.——
3264RESILIO THERAPEUTICS, LLC——
3265GCFREE, INC.——
3266NIGHTSTAR BIOTECHNOLOGIES, INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.